Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 [2]

Journal of Medicinal Chemistry

Volumn 43, Issue 17, 2000, Pages 3205-3208

  Garcia Echeverria, C ^a   Chene, P ^a   Blommers, M J J ^a   Furet, P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CONFORMATION; DRUG BINDING; DRUG SCREENING; DRUG STRUCTURE; LETTER; PHARMACOPHORE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE;

AMINO ACID SUBSTITUTION; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; MODELS, MOLECULAR; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034710708     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990966p     Document Type: Letter

References (37)

1. Keeping on old friend under control: Regulation of p53 stability
2. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
3. New insights into p53 function from structural studies
4. The p53 tumour suppressor
5. Discerning the function of p53 by examining its molecular interactions
6. p53 Function and dysfunction
7. Mutations in the p53 tumor suppresor gene: Clues to cancer etiology and molecular pathogenesis
8. Molecular analysis and chromosamal mapping of amplified genes isolated from a transformed mouse 3T3 cell line
9. The mdm2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
10. Amplification of a gene encoding a p53-associated protein in human sarcomas
11. The mdm2 oncogene can overcome wild-type p53 suppresion of transformed cell growth
12. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
13. Mdm2 gene amplification in metastatic osteosarcoma
14. Mutation and mdm2 amplification in human soft tissue sarcomas
15. Amplification of a gene encoding a p53-associated portein in human sarcomas
16. Mdm2 promotes the rapid degradation of p53
17. Regulation of p53 stability by mdm2
18. Immunochemical analysis of the interaction of p53 with mdm2; fine mapping of the mdm2 binding site on p53 using synthetic peptides
19. A genetic approach to mapping the p53 binding site in the mdm2 protein
20. Molecular characterization of the mdm2-p53 interaction
21. Identification of novel mdm2 binding peptides by phage display
22. Structure of the mdm2 oncoprotein bound to the p53 tumor suppresor transactivation domain
23. Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template
24. In vitro structure-function analysis of the β-strand 326-333 of human p53
25. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms
26. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
27. Factors governing helical preference of peptides containing multiple α,α-dialkyl amino acids
28. 3c homooligopeptides
29. Preferred conformations of peptides containing α,α-disubstituted α-amino acids
30. Structures of polypeptides from α-amino acids disubstituted at the α-carbon
31. The chemical shift index: A fast and simple method for the assignment of protein secondary structure through NMR spectroscopy
32. Computational alanine scanning to probe protein - Protein interactions: A novel approach to evaluate binding free energies
33. Design and synthesis of small molecule inhibitors of the mdm2-p53 interaction as potential antitumor agents
34. Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity